BEIJING, July 28, 2014 /PRNewswire/ — VisionChina Media Inc. (“VisionChina Media” or the “Company”) (Nasdaq: VISN), one of China’s largest out-of-home digital television advertising networks on mass transportation systems, today announced it has forme…
MUNICH, July 28, 2014 /PRNewswire/ — ET Solar Energy Corp. (“ET Solar”), a leading smart energy solutions provider, announced that it has supplied 10 MW high quality Anti-glare Modules to a solar power plant located in Obermeitingen, Germany.
The International Society of Aesthetic Plastic Surgery Releases Statistics on Cosmetic Procedures Worldwide
NEW YORK, July 28, 2014 /PRNewswire/ — More than 23 million cosmetic surgical and nonsurgical procedures were performed worldwide in 2013, according to statistics released today by the International Society of Aesthetic Plastic Surgery (ISAPS), the leading international society for aesthetic plastic surgery with more than 2,700 board-certified aesthetic plastic surgeon members in 95 countries. For the first time, Brazil edges out the United States in terms of the number of surgical procedures performed, and Botulinum Toxin takes the number one position for number of overall cosmetic procedures performed.
For the full report of ISAPS statistics along with a press release and a Quick Facts reference guide, click here.
As ISAPS prepares to host its 22nd Biennial Congress in Rio de Janeiro, Brazil in September, this new data will spark debate among the surgeons gathering from 75 countries to share new techniques and discuss cutting-edge information about this expanding field.
“Since our last survey was conducted, we have improved our strategy for gathering data based on statistically sound samples,” noted Carlos Uebel, MD, ISAPS president. “This has been an effort on the part of our society to further enhance our survey methodology and make it more comprehensive,” he continued.
The countries that performed the most cosmetic surgical and nonsurgical procedures in 2013 include:
- United States – 3,996,631 — (17%)
- Brazil– 2,141,257 — (9.1%)
- Mexico – 884,353 — (3.8%)
- Germany – 654,115 — (2.8%)
- Spain – 447,177 — (1.9%)
The leading cosmetic surgical procedures performed in 2013 were:
- Breast Augmentation — (1,773,584)
- Liposuction (1,614,031)
- Blepharoplasty (1,379,263)
- Lipostructure including lipofilling and stem-enhanced lipofilling (1,053,890)
- Rhinoplasty (954,423)
The leading nonsurgical procedures performed were:
- Botulinum Toxin (5,145,189)
- Fillers and Resorbables (3,089,686)
- Laser Hair Removal (1,440,252)
- Non-Invasive Facial Rejuvenation (1,307,300)
- Chemical Peel, CO2 resurfacing, dermabrasion (773,442)
Women had more than 20 million cosmetic procedures; 87.2% of the total. The surgical procedures performed most frequently on women in 2013 were:
- Breast Augmentation
- Breast Lift
Men had more than 3 million cosmetic procedures; 12.8% of the total. The surgical procedures performed the most frequently on men in 2013 were:
- Breast Reduction for Gynecomastia
ISAPS’ latest statistics indicate that cosmetic surgery is on the rise on a global scale. Rankings are based solely on those countries from which a sufficient survey response was received and data were considered to be representative.
PHILADELPHIA, July 28, 2014 /PRNewswire/ — The Intellectual Property and Science Business of Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead’s Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment — $1,000 per pill.
Hepatitis is an inflammation of the liver and there are five main hepatitis viruses, referred to as types A, B, C, D and E — plus types X and G. The five main types are of the greatest concern because of the burden of illness and death they cause and the potential for epidemic outbreaks. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer, killing close to 1.4 million every year according to the World Health Organization (WHO).
In late 2013, Gilead dramatically changed the hepatitis C treatment landscape with the launch of Sovaldi, an effective cure for many when used in combination with ribavirin. However, the high cost of the treatment keeps it out of reach for the majority of the estimated 130-150 million individuals suffering from the disease.
To raise additional awareness for World Hepatitis Day, Life Sciences Connect analysts complied Sovaldi-Innovative, Cost Effective, Unaffordable, utilizing Cortellis™Competitive Intelligence, the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content, to evaluate the current outlook of therapies in the pipeline. The analysis revealed several alternative treatments in various stages of development. This high activity is expected to create competition that will lessen costs of treatment, making it more affordable and accessible to patients.
The following were among the key treatments found in different stages of development:
Drug & Mechanism of Action
Indications Under Development
a nucleoside analog NS5B
Phase II for Hepatitis
orally available combination
Potential launch in 2015
veruprevir (HCV NS3/4A protease
Expected launch Q1 2015
The analysis also includes an infographic illustrating significant shifts in the Hepatitis drug market.
“We conducted this study in recognition of World Hepatitis Day to help raise awareness around this potentially devastating disease and spotlight some drugs in development that may help eradicate it,” said Jon Brett-Harris, managing director of Thomson Reuters IP & Science. “One of the largest barriers in treating hepatitis is accessibility, therefore it is critical to identify the key drugs in development that may help make treatment more attainable.”
Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions
HONG KONG, July 28, 2014 /PRNewswire/ — Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that its new PicoWay® device has received CE Mark indication to treat tattoos of all types and colors and pigmented lesions on any skin type. PicoWay is a new and innovative dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes Syneron’s proprietary PicoWay technology to deliver energy to the skin using pulses which are trillionths of a second, known as picosecond pulses. Syneron will begin a staged launch of the PicoWay device in the international market during the third quarter of 2014 and anticipates that it will receive U.S. Food and Drug Administration (FDA) clearance for PicoWay by the end of 2014.
PicoWay’s high peak power and ultra-short pulse duration enable a unique mode of action which creates the strongest photo-mechanical impact to break up the tattoo ink or the pigmentation. This revolutionary PicoWay technology is integrated into a proven, reliable Candela® platform which ensures superior performance and low cost of ownership.
“Our investment in PicoWay’s research and development demonstrate Syneron’s commitment to develop technology that enables physicians to provide best-in-practice treatments for their patients,” stated Amit Meridor, CEO of Syneron. “Since PicoWay has the shortest picosecond pulse duration and the highest peak power of any device on the market, we believe that fewer treatments will be needed and that the percentage clearance will be higher. We are pleased that Dr. Chan will present his positive results with PicoWay at IMCAS Asia, particularly because it will be a significant market for PicoWay due to the special value placed on clear skin in Asia.”
Dr. Henry Chan, specialist in dermatology in Hong Kong, will present the interim results of a multi-center study focused on treating pigmented lesions with PicoWay at the IMCAS Asia Conference slated for August 1-3, 2014 in Hong Kong. His presentation is entitled “The Use of Picosecond Lasers on Asians”.
Dr. Chan says “PicoWay’s unique mode of picosecond action enables full flexibility to adjust the wavelength, fluence, spot size and rep rate, providing customizable treatments which ensure outstanding clinical results. The novel PicoWay technology enables our clinic to offer a new and exciting solution to remove pigmented lesions. The treatments have proven to be effective, safe and comfortable with a high satisfaction rate among our patients.”
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, treatment results, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Company’s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.’s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.’s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Additional information can be found at www.syneron-candela.com
ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
— Trial court awards permanent injunction, damages and costs against APEX
MUNICH, July 28, 2014 /PRNewswire/ — ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks. The judgment was entered by the Regional District Court in Munich, is appealable, and applies throughout Germany.
The permanent injunction continues a preliminary injunction that was entered by the same court on Nov. 12, 2013. The court rejected APEX’s request to stay the injunction and its challenge to the validity of ResMed’s patent. The judgment also requires APEX to forfeit its inventory of infringing products, to report on its sales of the infringing products, and to pay damages to ResMed.
ResMed has also filed separate patent infringement lawsuits in the same court seeking damages and permanent injunctions to stop infringement of other ResMed patents. The trials of those cases will occur in the fall of 2014. The additional accused products are:
- The APEX iCH and XT Fit CPAP devices
- The APEX WiZARD 210 and WiZARD 220 masks
“ResMed has a global business built on its investment in research and developments, resulting in products sold worldwide that excel in performance, quality and comfort,” said David Pendarvis, ResMed global general counsel and chief administrative officer. “We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists.”
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
Director, Global Corporate Communications
Senior Director, Investor Relations
Yingli Green Energy Comments on U.S. Department of Commerce’s Preliminary Decision on Anti-Dumping Tariffs for Certain Imported Solar Products
BAODING, China, July 28, 2014 /PRNewswire/ — Yingli Green Energy Holding Company Limited (NYSE: YGE) (“Yingli Green Energy” or the “Company,”) the largest vertically integrated photovoltaic (“PV”) module manufacturer in the world, known as “Yingli Sol…
BEIJING, July 28, 2014 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnos…
BEIJING, July 28, 2014 /PRNewswire/ — Exceed Company Ltd. (EDS) (“Exceed” or the “Company”), one of the leading domestic sportswear brands in China, today announced that it intends to further adjourn its extraordinary general meeting of shareholders t…
BEIJING, July 28, 2014 /PRNewswire/ — Hollysys Automation Technologies, Ltd. (NASDAQ: HOLI) (“Hollysys” or the “Company”), a leading provider of automation and control technologies and applications in China, today announced that Mr. Baiqing Shao, CEO …